101. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
- Author
-
Megan Griffith, Tom Cairns, Damien Ashby, Liz Lightstone, Marie B Condon, H. Terence Cook, Jeremy Levy, and Ruth J. Pepper
- Subjects
Adult ,Male ,Nephrology ,medicine.medical_specialty ,Immunology ,Lupus nephritis ,Methylprednisolone ,Gastroenterology ,General Biochemistry, Genetics and Molecular Biology ,Mycophenolic acid ,Cohort Studies ,Antibodies, Monoclonal, Murine-Derived ,Young Adult ,chemistry.chemical_compound ,Rheumatology ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,Prospective Studies ,Prospective cohort study ,Aged ,Creatinine ,Proteinuria ,Drug Substitution ,business.industry ,Remission Induction ,Middle Aged ,Mycophenolic Acid ,Creatine ,medicine.disease ,Lupus Nephritis ,Treatment Outcome ,chemistry ,Drug Therapy, Combination ,Female ,Rituximab ,medicine.symptom ,business ,Immunosuppressive Agents ,medicine.drug - Abstract
Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE). All current treatment regimens include oral steroids, which are associated with severe adverse events and long-term damage. We have piloted a steroid-avoiding protocol (rituxilup) for the treatment of biopsy-proven active International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III, IV, or class V LN.We report the findings from the first 50 consecutive patients, treated with 2 doses of rituximab (1 g) and methyl prednisolone (500 mg) on days 1 and 15, and maintenance treatment of mycophenolate mofetil. Patients on maintenance steroids or with life-threatening SLE or requiring dialysis were excluded. Renal remission was defined as serum creatinine no greater than 15% above baseline; complete biochemical remission (CR) was defined as urine protein : creatinine ratio (PCR)50 mg/mmol or partial remission (PR) if PCR50 mg/mmol but non-nephrotic and50% reduction.A total of 45 (90%) patients achieved CR or PR by a median time of 37 weeks (range 4-200). Overall, 72% (n=36) achieved CR (median time 36 weeks (11-58)) and a further 18% (n=9) achieved persistent PR (median time 32 weeks (19-58)). By 52 weeks, CR and PR had been achieved in 52% (n=26) and 34% (n=17) respectively. In all, 12 relapses occurred in 11 patients, at a median time of 65.1 weeks (20-112) from remission. A total of 6/50 patients had systemic flares. Of the 45 responders, only 2 required2 weeks of oral steroids. Adverse events were infrequent; 18% were admitted, 10% for an infective episode.The rituxilup cohort demonstrates that oral steroids can be safely avoided in the treatment of LN. If findings are confirmed, it could mark a step change in the approach to the treatment of LN.
- Published
- 2013
- Full Text
- View/download PDF